The nation of Zimbabwe has turned down a significant American health deal worth 367 million US dollars (£272m) spanning five years due to Washington's request for sensitive biological samples.
This rejection came to light following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
A government representative later stated that the United States was requesting biological samples for research and commercial gain but was not willing to guarantee the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more dialogue to find a deal suitable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
This rejection comes after a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were filed about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
As per statements, Sixteen African countries have to date agreed to these new agreements, representing over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation might have yielded extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," he stated.
"Put simply, our country would supply the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our population if a new disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending frameworks previously set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This mechanism is intended to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to further discussions with our US partners on how subsequent collaboration might be designed in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body expressed it acknowledged the government's concerns, but recommended that talks need to persist considering much of the country's HIV programmes relied on international support.
"Where technical issues exist, including those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it commented.
The halted deal emphasises the complex debate between receiving crucial foreign assistance and protecting local interests in an increasingly data-driven world.